Baidu
map

以色列口服胰岛素研发获新突破 牵动资本神经

2013-12-26 上海证券报 上海证券报

在美上市的以色列医药公司Oramed医药上20日宣布,该公司的独家新药,口服胰岛素ORMD-0801二期临床测试成功,在欧洲获得了专利获批,将被允许在欧洲以及承认欧洲药监局条例的主要国家作为一型糖尿病的治疗药物使用。公司股价随即脉冲式上涨,在过去五个交易日累计涨幅115.83%,阶段涨幅在美股所有股票中名列第一。 众所周知,胰岛素的使用主要通过注射给药,给广大糖尿病患者带来很多不便,亟待开发出新

在美上市的以色列医药公司Oramed医药上20日宣布,该公司的独家新药,口服胰岛素ORMD-0801二期临床测试成功,在欧洲获得了专利获批,将被允许在欧洲以及承认欧洲药监局条例的主要国家作为一型糖尿病的治疗药物使用。公司股价随即脉冲式上涨,在过去五个交易日累计涨幅115.83%,阶段涨幅在美股所有股票中名列第一。

众所周知,胰岛素的使用主要通过注射给药,给广大糖尿病患者带来很多不便,亟待开发出新的给药途径。受制于胰岛素自身易被胃酸降解,难以发挥疗效等因素影响,口服胰岛素的研发一直是这一领域公认的难题。口服胰岛素一旦研发成功将极大地改善胰岛素依赖型糖尿病患者的生活质量,因此其巨大的市场应用前景一直牵动着资本市场的神经。

在今年1月,Oramed曾向美国食品药品监督管理局提交了关于ORMD-0801二期临床的新药研究申请。根据临床测试的要求,一型糖尿病病人被要求在不同研究阶段摄入不同剂量的口服胰岛素,通过对病人的血葡萄糖指标与摄入剂量的对比,研究人员证实ORMD-0801的摄入剂量与药效存在正相关联系。在获得欧盟批准之前,口服胰岛素ORMD-0801已在新西兰、南非等全球27个国家获得专利保护。今年九月,公司就曾宣布获得了中国国家知识产权局向其颁发的关于其口服药物核心技术专利。Oramed的CEONadavKidron在接受采访时表示,临床测试的良好结果让公司振幅,公司将继续推进口服胰岛素在二型糖尿病领域的研究。

一型糖尿病原名胰岛素依赖型糖尿病,患者体内的胰岛素生成细胞因病被破坏,导致体内胰岛素不足,容易发生酮症酸中毒,必须用胰岛素治疗才能获得满意疗效,否则将危及生命。据统计,全球目前有3600万一型糖尿病患者,并且正以每年3%的速度增长。

全球胰岛素市场目前规模大约为140亿美元,中国已是世界上糖尿病第二大高发国,患者超过1亿人,且呈继续增长态势;因此口服胰岛素在我国同样拥有巨大市场空间,亚宝药业涉及相关研发。而国内多家A股上市公司涉及胰岛素的生产。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1724872, encodeId=f09b1e248728b, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Aug 11 03:55:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749456, encodeId=0afb1e49456a9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 21 10:55:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719263, encodeId=9c871e19263a7, content=<a href='/topic/show?id=12b792553da' target=_blank style='color:#2F92EE;'>#资本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92553, encryptionId=12b792553da, topicName=资本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef5032698226, createdName=kord1993, createdTime=Thu Jun 05 05:55:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299768, encodeId=b5eb1299e6863, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Dec 28 06:55:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420611, encodeId=286b1420611a9, content=<a href='/topic/show?id=787b38232d6' target=_blank style='color:#2F92EE;'>#口服胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38232, encryptionId=787b38232d6, topicName=口服胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19a3601771, createdName=by2010, createdTime=Sat Dec 28 06:55:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1724872, encodeId=f09b1e248728b, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Aug 11 03:55:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749456, encodeId=0afb1e49456a9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 21 10:55:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719263, encodeId=9c871e19263a7, content=<a href='/topic/show?id=12b792553da' target=_blank style='color:#2F92EE;'>#资本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92553, encryptionId=12b792553da, topicName=资本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef5032698226, createdName=kord1993, createdTime=Thu Jun 05 05:55:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299768, encodeId=b5eb1299e6863, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Dec 28 06:55:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420611, encodeId=286b1420611a9, content=<a href='/topic/show?id=787b38232d6' target=_blank style='color:#2F92EE;'>#口服胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38232, encryptionId=787b38232d6, topicName=口服胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19a3601771, createdName=by2010, createdTime=Sat Dec 28 06:55:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
    2014-05-21 baoya
  3. [GetPortalCommentsPageByObjectIdResponse(id=1724872, encodeId=f09b1e248728b, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Aug 11 03:55:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749456, encodeId=0afb1e49456a9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 21 10:55:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719263, encodeId=9c871e19263a7, content=<a href='/topic/show?id=12b792553da' target=_blank style='color:#2F92EE;'>#资本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92553, encryptionId=12b792553da, topicName=资本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef5032698226, createdName=kord1993, createdTime=Thu Jun 05 05:55:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299768, encodeId=b5eb1299e6863, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Dec 28 06:55:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420611, encodeId=286b1420611a9, content=<a href='/topic/show?id=787b38232d6' target=_blank style='color:#2F92EE;'>#口服胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38232, encryptionId=787b38232d6, topicName=口服胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19a3601771, createdName=by2010, createdTime=Sat Dec 28 06:55:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
    2014-06-05 kord1993
  4. [GetPortalCommentsPageByObjectIdResponse(id=1724872, encodeId=f09b1e248728b, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Aug 11 03:55:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749456, encodeId=0afb1e49456a9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 21 10:55:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719263, encodeId=9c871e19263a7, content=<a href='/topic/show?id=12b792553da' target=_blank style='color:#2F92EE;'>#资本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92553, encryptionId=12b792553da, topicName=资本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef5032698226, createdName=kord1993, createdTime=Thu Jun 05 05:55:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299768, encodeId=b5eb1299e6863, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Dec 28 06:55:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420611, encodeId=286b1420611a9, content=<a href='/topic/show?id=787b38232d6' target=_blank style='color:#2F92EE;'>#口服胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38232, encryptionId=787b38232d6, topicName=口服胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19a3601771, createdName=by2010, createdTime=Sat Dec 28 06:55:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]
    2013-12-28 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=1724872, encodeId=f09b1e248728b, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Aug 11 03:55:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749456, encodeId=0afb1e49456a9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 21 10:55:00 CST 2014, time=2014-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719263, encodeId=9c871e19263a7, content=<a href='/topic/show?id=12b792553da' target=_blank style='color:#2F92EE;'>#资本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92553, encryptionId=12b792553da, topicName=资本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef5032698226, createdName=kord1993, createdTime=Thu Jun 05 05:55:00 CST 2014, time=2014-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299768, encodeId=b5eb1299e6863, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Dec 28 06:55:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420611, encodeId=286b1420611a9, content=<a href='/topic/show?id=787b38232d6' target=_blank style='color:#2F92EE;'>#口服胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38232, encryptionId=787b38232d6, topicName=口服胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f19a3601771, createdName=by2010, createdTime=Sat Dec 28 06:55:00 CST 2013, time=2013-12-28, status=1, ipAttribution=)]

相关资讯

CHMP建议有条件批准强生结核病药物Sirturo

上周五,强生(JNJ)结核病药物Sirturo(bedaquiline,双芳基喹啉类抗结核药)获得了欧洲药品管理局(EMA)人用医药产品委员会(CHMP)的积极意见。CHMP建议授予Sirturo有条件上市许可(conditional marketing authorisation),将该药作为组合疗法的一部分,用于因耐药性或耐受性使得一种有效治疗方案不能用于其临床治疗的耐多药结核病(multid

CHMP建议批准罗氏皮下注射剂型RoACTEMRA

罗氏(Roche)皮下注射(subcutaneous,SC)剂型RoACTEMRA(欧洲以外名为ACTEMRA,通用名:tocilizumab,托珠单抗)获得了欧洲药品管理局(EMA)人用医药产品委员会(CHMP)的积极意见。CHMP建议批准皮下注射剂型RoACTEMRA,用于既往经一种或多种疾病修饰抗风湿药物(DMARDs)或肿瘤坏死因子(TNF)抑制剂治疗反应不足、或对这些药物不耐受的中度至重

GSK新复方药Anoro Ellipta获FDA批准

葛兰素史克(GSK)和Theravance制药上周联合宣布,新复方药Anoro Ellipta已获FDA批准,作为每日一次的吸入性疗法,用于慢性阻塞性肺病(COPD)患者的长期维持治疗,包括慢性支气管炎和肺气肿。Anoro Ellipta不适用于急性支气管痉挛(acute bronchospasm)的缓解或哮喘(asthma)的治疗。 GSK计划于2014年第一季度在美国推出Anoro El

FDA授予GSK药物tafenoquine突破性疗法认定

葛兰素史克(GSK)与非营利组织“抗疟药品事业会”(Medicines for Malaria Venture,MMV)12月20日联合宣布,FDA已授予他非诺喹(tafenoquine)突破性疗法认定,tafenoquine是一种实验性药物,正开发用于间日疟(Plasmodium vivax malaria)的治疗和预防复发。目前,tafenoquine尚未获任何监管批准。 间日疟(P.v

诺和诺德向FDA及EMA提交liraglutide监管文件

诺和诺德(Novo Nordisk)12月20日宣布,已分别向美国食品和药物管理局(FDA)和欧洲药品管理局(EMA)提交了高剂量利拉鲁肽(liraglutide,3mg)的新药申请(NDA)和上市许可申请(MAA)。 liraglutide是一种每日一次的人胰高糖素样肽-1(GLP-1)类似物,作为低热量饮食和增加体力活动的辅助药物,用于肥胖症或超重合并症成人患者的体重管理。 lirag

武田在日本提交甲吡唑新药申请

武田(Takeda)12月25日宣布,已向日本卫生劳动福利部(MHLW)提交了甲吡唑(fomepizole)的新药申请(NDA),该药用于治疗乙二醇(ethylene glycol)和甲醇(methanol)中毒。 甲吡唑是一种乙醇脱氢酶抑制剂,由Paladin Labs在加拿大销售和分销,该药是治疗乙二醇和甲醇中毒的标准药物。2011年5月,武田与Paladin达成了授权和分销协议,目前,在日

Baidu
map
Baidu
map
Baidu
map